Safety and Immunogenicity of a Booster SARS-Cov-2 Vaccination in Patients with Chronic Liver Disease
Qianqian, L.; Jing, C.; Kai, S.; Ruixin, S.; Jiayin, W.; Hongmin, L.; Yankai, Y.; Jing, L.; Qing, Y.; YanYing, G.; Jun, L.; Ying, L.; Junqing, Y.; Chao, Y.; Ying, L.; Tao, W.; Changen, L.; Fei, W.; Huiling, X.
Show abstract
This article is aim to investigate the safety and immunogenicity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine booster in patients with chronic liver disease(CLD). A total of 114 patients with CLD who received a SARS-CoV-2 vaccine booster were enrolled in this study. Serum samples were collected from enrolled patients at least 14 days after the booster dose and tested for SARS-CoV-2 neutralizing antibody (novel coronavirus neutralizing antibody, nCoV NTAb) and IgG antibody against SARS-CoV-2 spike binding domain (novel coronavirus spike receptor-binding domain antibody, nCoV S-RBD antibody) levels. The positive rates of nCoV NTAb and nCoV S-RBD in patients with CLD were 87.72% and 91.23%, respectively, after the booster injection of coronavirus disease 2019 (COVID-19) vaccine. The booster injection resulted in the production of nCov NTAb in 66.7% of patients and nCov-SRBD antibody in 71.43% of patients with CLD who failed basic immunization. After basic SARS-CoV-2 immunization, the booster SARS-CoV2 vaccine increased the serum conversion rate and the level of nCov NTAb and nCov-SRBD antibodies in patients with CLD (including patients with cirrhosis). The severity of the liver disease is related to the immune response to COVID-19 vaccine.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The Impact of Coronavirus Disease 2019 (COVID-19) on Liver Injury in China: A Systematic Review and Meta-analysis 94%
- Upregulation of ARHGAP9 is correlated with poor prognosis and immune infiltration in clear cell renal cell carcinoma 91%
- Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India 91%
Similar papers in this journal
- Predictors of In-hospital Mortality among Cirrhotic Patients in Ethiopia: A Multicenter Retrospective Study 96%
- PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response 94%
- GSEA and the coexpression network approach identify novel pathway connections of molecular processes affected in Porto-sinusoidal vascular disease. 94%
Similar papers in this journal
- Transcriptome analysis of PBMCs reveals distinct immune response in the asymptomatic and re-detectable positive COVID-19 patients 92%
- Safety and immunogenicity of GamEvac-Combi, a heterologous rVSV- and rAd5-vectored Ebola vaccine: a randomized controlled multicenter clinical trial in the Republic of Guinea and Russia 92%
- Circulatory Cytokines and Chemokines Profile in Human Coronaviruses: A systematic review and meta-analysis 92%
Similar papers in this journal
- Immune response after SARS-CoV-2 infection with residual post COVID symptoms 94%
- Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine 94%
- Clinical advancement of patients infected with SARS-CoV-2 Omicron variant in Shanghai, China 93%
Similar papers in this journal
- Comprehensive genomic, immunological and clinical analysis of COVID-19 vaccine breakthrough infections: a prospective, comparative cohort study 95%
- Relative expression of pro-inflammatory molecules in COVID-19 patients manifested disease severities 94%
- Anti-SARS-CoV-2 IgG profile of protein subunit, adenovector and mRNA vaccines 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.